J&J's blockbuster hopeful erdafitinib gets 'breakthrough' moniker
Janssen has snagged the FDA’s breakthrough status on its solid tumor drug candidate erdafitinib, putting J&J one step closer to its lofty goal of bringing numerous new blockbuster drugs to market.
The drug, an FGFR inhibitor, got the designation for its potential to treat patients with metastatic urothelial cancer. Urothelial cancer is the sixth most common type of cancer in the US, most frequently showing up in the bladder.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.